(Washington Post) Weight-loss drugs aren’t just slimming waists. They’re shifting the economy.

[Right now there are]…16 million people — that’s 6 percent ofAmerican adults — taking GLP-1 weight-loss drugs, and their collective purchasing power has the potential to profoundly reshape the economy in the coming years.

There’s evidence that the demographic of people on the drugs overlaps with those who like to spend, a group some analysts have dubbed “over consumers.” Cutting their daily calorie counts in half — or more — is resulting in all sorts of interesting consequences still coming to light.

Ozempic, and its GLP-1 cousins Mounjaro, Wegovy and Zepbound, may not be the lightbulb, jet airplane or internet, but their impact is expected to be so significant that Jan Hatzius, chief economist at Goldman Sachs, predicts that if 60 million people take the medications by 2028, GDP would be boosted by 1 percent — or several trillion dollars. Hatzius’s analysis was based primarily on the idea that healthier people mean a healthier workforce and, in turn, lower health-care costs.

But there’s a lot more to it.

Read it all.

Weight-loss drugs aren’t just slimming waists. They’re shifting the economy. https://t.co/y9Ikk6SLxr

— Nick Baumann (@NickBaumann) February 23, 2025